BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors

To analyze responsiveness of gastric cancer to PARP inhibitor, scientists exploited a gastroesophageal adenocarcinoma platform of patient-derived xenografts (PDX) and PDX-derived primary cells and selected 10 PDXs with loss-of-function mutations in HR pathway genes.